Multigene Testing for Hereditary Cancer: When, Why, and How

Restricted access

Multigene testing is a complicated area, with advantages and disadvantages of testing for hereditary cancer syndromes. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian and Colorectal provide suggestions for mutation carriers identified by panel tests.

Correspondence: Kenneth Offit, MD, MPH, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E-mail: offitk@mskcc.org
  • 1.

    Daly MB, Pilarski R, Berry M. NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2017. Accessed April 5, 2017.

    • Search Google Scholar
    • Export Citation
  • 2.

    Provenzale D, Gupta S, Ahnen DJ. NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2016. Accessed April 5, 2017.

    • Search Google Scholar
    • Export Citation
  • 3.

    Pritchard CC, Mateo J, Walsh MF. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375:443453.

  • 4.

    Domchek SM, Bradbury A, Garber JE. Multiplex genetic testing for cancer susceptibility. J Clin Oncol 2013;31:12671270.

  • 5.

    Balmaña J, Digiovanni L, Gaddam P. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. J Clin Oncol 2016;34:40714078.

    • Search Google Scholar
    • Export Citation
  • 6.

    Vogel VG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 2001;16(18 Suppl):87S92S.

  • 7.

    Tung N, Domchek S, M, Stadler Z. Counseling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016;13:581588.

    • Search Google Scholar
    • Export Citation
  • 8.

    Trosman JR, Weldon CB, Douglas MP. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the Precision Medicine Initiative. J Natl Compr Canc Netw 2017.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 233 152 15
PDF Downloads 99 80 6
EPUB Downloads 0 0 0